Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 2032-2037

  Graesslin, Olivier ^a   Abdulkarim, Bassam S ^a   Coutant, Charles ^a   Huguet, Florence ^a   Gabos, Zsolt ^a   Hsu, Limin ^a   Marpeau, Olivier ^a   Uzan, Serge ^a   Pusztai, Lajos ^a   Strom, Eric A ^a   Hortobagyi, Gabriel N ^a   Rouzier, Roman ^a   Ibrahim, Nuhad K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; ELECTRONIC MEDICAL RECORD; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; BRAIN TUMOR; BREAST TUMOR; CANADA; CANCER STAGING; FEMALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANADA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951647270     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.6314     Document Type: Article

References (32)

1. DiStefano A, Yong Yap Y, Hortobagyi GN, et al: The natural history of breast cancer patients with brain metastases. Cancer 44:1913-1918, 1979
2. Tsukada Y, Fouad A, Pickren JW, et al: Central nervous system metastasis from breast carcinoma: Autopsy study. Cancer 52:2349-2354, 1983 (Pubitemid 14205961)
3. Engel J, Eckel R, Aydemir U, et al: Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55:1186-1195, 2003 (Pubitemid 36338283)
4. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004 (Pubitemid 38670323)
5. Klos KJ, O'Neill BP: Brain metastases. Neurologist 10:31-46, 2004 (Pubitemid 38140837)
6. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 22:3608-3617, 2004 (Pubitemid 41103668)
7. Hicks DG, Short SM, Prescott NL, et al: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30:1097-1104, 2006 (Pubitemid 44299342)
8. Pestalozzi BC, Zahrieh D, Price KN, et al: Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944, 2006
9. Tham YL, Sexton K, Kramer R, et al: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107:696-704, 2006 (Pubitemid 44232661)
10. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003 (Pubitemid 36676250)
11. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643, 2004 (Pubitemid 39141617)
12. Shmueli E, Wigler N, Inbar M: Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379-382, 2004 (Pubitemid 38121275)
13. Yau T, Swanton C, Chua S, et al: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196-201, 2006
14. Bria E, Cuppone F, Fornier M, et al: Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109:231-239, 2008 (Pubitemid 351644860)
15. Lai R, Dang CT, Malkin MG, et al: The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810-816, 2004 (Pubitemid 39030939)
16. Lower EE, Drosick DR, Blau R, et al: Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4:114-119, 2003 (Pubitemid 36939417)
17. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
18. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
19. Dawood S, Broglio K, Esteva FJ, et al: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19: 1242-1248, 2008 (Pubitemid 351911952)
20. Heitz F, Harter B, Beutel B, et al: Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 26:43s, 2008 (suppl; abstr 1010)
21. Pinder MC, Chang H, Broglio KR, et al: Trastuzumab treatment and the risk of central nervous system (CNS) metastases. J Clin Oncol 25:36s,2007 (suppl; abstr 1018)
22. Sawrie SM, Meredith RF, Spencer SA, et al: HER2-neu status as a predictor of survival in patients with brain metastases from primary breast adenocarcinoma. J Clin Oncol 25:36s, 2007 (suppl; abstr 1016)
23. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658-5663, 2006 (Pubitemid 46631306)
24. Coutant C, Olivier C, Lambaudie E, et al: Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: A prospective multicenter study. J Clin Oncol 27:2800-2808, 2009
25. Bos PD, Zhang XH, Nadal C, et al: Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009, 2009
26. Rouzier R, Pusztai L, Delaloge S, et al: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-8339, 2005
27. Schroeck FR, Aronson WJ, Presti JC Jr, et al: Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int 103:603-608, 2009
28. Shariat SF, Capitanio U, Jeldres C, et al: Can nomograms be superior to other prediction tools? BJU Int 103:492-495, 2009
29. Patel S, Macdonald OK, Suntharalingam M: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 115:842-850, 2009
30. Slotman B, Faivre-Finn C, Kramer G, et al:Prophylactic cranial irradiation in extensive smallcell lung cancer. N Engl J Med 357:664-672, 2007 (Pubitemid 47267236)
31. Stuschke M, Eberhardt W, Pottgen C, et al: Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700-2709, 1999 (Pubitemid 29415226)
32. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998 (Pubitemid 28439961)